For the year ending 2025-12-31, SSKN had -$683K decrease in cash & cash equivalents over the period. -$4,262K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -6,261 |
| Depreciation and amortization | 4,123 |
| Impairment of goodwill | 0 |
| Amortization of operating lease right-of-use assets | 344 |
| Amortization of deferred financing costs and debt discount | 157 |
| Provision for credit losses | 129 |
| Stock-based compensation expense | 643 |
| Loss on disposal of property and equipment | -92 |
| Settlement gains | 1,135 |
| Inventory write-off | 0 |
| Deferred income taxes | 0 |
| Accounts receivable | -1,003 |
| Inventories | 288 |
| Prepaid expenses and other assets | 252 |
| Accounts payable | 350 |
| Accrued expenses and other liabilities | -1,248 |
| Deferred revenues | -123 |
| Operating lease liabilities | -328 |
| Net cash (used in) provided by operating activities | -2,794 |
| Purchase of property and equipment | 1,468 |
| Net cash used in investing activities | -1,468 |
| Payment of contingent consideration | 0 |
| Sale of common stock, net of offering costs | 3,579 |
| Net cash provided by financing activities | 3,579 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -683 |
| Cash, cash equivalents and restricted cash at beginning of year | 8,595 |
| Cash, cash equivalents and restricted cash at end of year | 7,912 |
STRATA Skin Sciences, Inc. (SSKN)
STRATA Skin Sciences, Inc. (SSKN)